Member Info for Bermudashorts

The Biotech and Money awards are due to take place on 6th Sep in London. Angle have been shortlisted as a finalist in the category - "'ONE TO WATCH' PUBLIC UK LIFE SCIENCE COMPANY IN 2017 AWARD" http://www.biotechandmoney.com/ceo-gala-dinner-2016-awards

Yep excellent RNS - the IRT news is particularly significant. Good stuff. " I am particularly pleased with our success in IRT. Coming through the vendor qualification and audit process with "big-pharma" represents a significant step for our organisation and high quality execution of this initial project should result in a rich vein of new business." http://www.investegate.co.uk/venn-life-sciences--venn-/rns/contract-wins/201608030700080537G/

An upbeat Andrew Newland discussing results in Proactive interview this morning:- http://www.proactiveinvestors.co.uk/companies/stocktube/5333/angles-newland-reflects-on-incredible-year-as-cancer-patient-trials-advance-5333.html

Parsortix chosen for use in the EU funded GANNET53 Ganetespib clinical trial for ovarian cancer. "Following the Medical University of Vienna's results with ANGLE's Parsortix system showing "unprecedented sensitivity and specificity" announced on 27 January 2015, ANGLE were invited by the consortium to participate in the study." http://www.investegate.co.uk/angle-plc/agl/use-of-parsortix-in-gannet53-drug-trial/201607280700164571F/?fe=1&utm_source=FE%20Investegate%20Alerts&utm_medium=Email&utm_content=Announcement%20Alert%20Mail&utm_campaign=Angle PLC%20Alert

Excellent news from today's RNS, US study now initiated - link to Clinical Trials Register below. https://clinicaltrials.gov/ct2/show/NCT02781272?term=ANG-003+EMBER&rank=1

First patient recruited to ovarian cancer study. "Whilst the speed of patient recruitment is outside of ANGLE's control, the aim is to complete the study by 2016 calendar year end." Good stuff http://www.investegate.co.uk/angle-plc--agl-/rns/initiation-of-european-ovarian-cancer-study/201607190700075295E/

Interims - let's hope he's right "the Company remains on track to double 2015's operating profitability by 2017" http://www.investegate.co.uk/frenkel-topping-grp--fen-/rns/half-year-report/201607110700067248D/

Another very positive RNS. "As a breast cancer surgeon, I am very enthusiastic about the potential of liquid biopsy to gain information to guide the treatment of breast cancer patients based on the specific tumor biology for each patient. Our pilot data shows that potentially the same information can be obtained from a simple blood test using Parsortix as from an invasive tissue biopsy and indeed may be advantageous over invasive tissue biopsies in regards to the diverse sites of metastatic disease, thus providing a compelling rationale for use in clinical practice after further validation." Link to the relevant AACR abstract paper is below:- http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=0fddb9fe-7ef3-4a51-a653-1354768eaaa2&cKey=5bfde611-c1f7-4019-b485-b17431c6251e&mKey=%7b1D10D749-4B6A-4AB3-BCD4-F80FB1922267%7d

· Revenues up 43% to £30.2million (2014: £21.2m) · Gross profit up 45% to £8.4 million (2014: £5.8m) · EBITDA (adjusted) up 39% to £3.4 million (2014: £2.4m) · Strong backlog of £59 million with more than 85% of planned 2016 revenue already contracted as of 1 January 2016 "We continue to see good customer traction with contracts with an initial value of £28 million won in 2015 and the Company is poised for another excellent year in 2016. " http://www.investegate.co.uk/ergomed-plc--ergo-/rns/preliminary-results/201604120700068638U/

Results due on 12th April http://www.investegate.co.uk/ergomed-plc--ergo-/rns/notice-of-results/201603301200045460T/

Good coverage from The Telegraph http://www.telegraph.co.uk/business/2016/03/18/angle-unveils-promising-results-for-ground-breaking-prostate-can/

Angle PLC makes Prostate Cancer Breakthrough http://www.proactiveinvestors.co.uk/companies/news/123889

Yes very positive:- "Barts patient data suggests that the Parsortix system may be used both to detect prostate cancer and to assess its aggressiveness, all through a simple blood test." http://www.investegate.co.uk/angle-plc--agl-/rns/parsortix-potential-for-prostate-cancer-detection/201603210700116690S/

Good news:- "The granted European patent provides protection over a wide range of uses of the Parsortix technology and extends the duration of patent coverage out to 2034." http://www.investegate.co.uk/angle-plc--agl-/rns/european-patent-grant-for-parsortix/201603090700094749R/

Yes good news:- "This is our third peer-reviewed publication in a key scientific journal and adds to the growing body of published evidence of Parsortix's superior performance as a liquid biopsy. The demonstration of viability of the CTCs is notable and in stark contrast to competing approaches. Cell viability and easy harvesting of cells from blood are key capabilities that differentiate ANGLE's Parsortix system for the developing liquid biopsy market in cancer diagnosis and treatment."

Excellent news.

New CFO Stephen Stamp - impressive CV http://www.investegate.co.uk/ergomed-plc--ergo-/rns/ergomed-announces-board-changes/201601110700073628L/

For some reason the trading update doesn't appear to be showing on this site's RNS link so have link below in case any have missed it. Excellent update and particularly like this sentence:- " a cash position at year end of €3.4m and the business now generating free cashflows" http://www.investegate.co.uk/venn-life-sciences--venn-/rns/trading-update/201601080701022206L/

"ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech company, is pleased to announce the receipt of £0.7 million cash " http://www.investegate.co.uk/angle-plc--agl-/rns/completion-of-geomerics-transaction/201512220700057730J/

A useful snapshot of where the Company stands on each of its co-development partnerships. With final results due in 2016 from the phase III ZoptEC trial in endometrial cancer, Lorediplon phase IIa for insomnia and sevuparin phase II for sickle-cell disease next year is going to be very important for the partnership side of Ergomed's business. http://www.investegate.co.uk/ergomed-plc/ergo/ergomed-update-on-co-development-partnerships/201512160700071864J/?fe=1&utm_source=FE%20Investegate%20Alerts&utm_medium=Email&utm_content=Announcement%20Alert%20Mail&utm_campaign=Ergomed plc%20Alert